Lilly Acquires 4E Therapeutics to Boost Non-Opioid Chronic Pain Pipeline
LLY sits 83% above its 52-week low of $623.78.
Summary
Eli Lilly has acquired 4E Therapeutics to advance its non-opioid approach to chronic pain. While the financial terms of the transaction were not disclosed, this acquisition expands Lilly's pipeline into a significant therapeutic area with high unmet need. This move follows a period of intense activity for Lilly, including the recent FDA approval and positive trial results for its weight-loss drug Foundayo, and a prior $6.3 billion acquisition of Centessa's OX2R agonist assets. It signals Lilly's continued strategic investment in diversifying its drug portfolio.
At the time of this announcement, LLY was trading at $1,140.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.1T. The 52-week trading range was $623.78 to $1,182.73. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.